Roos Eva, van Coevorden Frits, Verhoef Cornelis, Wouters Michel W, Kroon Herman M, Hogendoorn Pancras C W, van Houdt Winan J
Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Surgical Oncology, Erasmus Medical Centre-Daniel den Hoed, Rotterdam, The Netherlands.
Ann Surg Oncol. 2016 Mar;23(3):811-7. doi: 10.1245/s10434-015-4932-2. Epub 2015 Oct 23.
Chondrosarcoma of the rib is a rare disease. Although surgery is the only curative treatment option, rib resection with an adequate margin can be challenging and local recurrence is a frequent problem. In this study, the prognosis of primary and recurrent chondrosarcoma of the rib is reported.
Retrospective analysis was performed of patients treated for chondrosarcoma of the rib between 1984 and 2014 in three major tertiary referral centers in The Netherlands. Clinical and histopathological features were analyzed for their prognostic value using Kaplan-Meier and Cox proportional hazard analysis. Endpoints were set at local recurrent disease, metastasis rate, or death.
Overall, 76 patients underwent a resection for a primary chondrosarcoma, and 26 patients underwent a resection for a recurrent chondrosarcoma. Five-year overall survival in the primary group was 90%, local recurrence rate was 17%, and metastasis rate was 12%. The 5-year outcome after recurrent chondrosarcoma was lower, with an overall survival of 65%, local recurrence rate of 27%, and metastasis rate of 27%. For primary chondrosarcoma, tumor size >5 cm and a positive resection margin were correlated with worse overall survival [hazard ratio (HR) 3.28, 95% confidence interval (CI) 1.03-10.44; HR 2.92, 95% CI 1.03-8.25). A higher histological grade was correlated with a higher local recurrence and metastasis rate (HR 5.92, 95% CI 1.11-31.65; HR 6.96, 95% CI 1.15-42.60).
Surgical resection of both primary and recurrent chondrosarcoma of the rib is an effective treatment strategy. The oncological outcome after surgery is worse in tumors >5 cm, in tumors with positive resection margins and grade 3 chondrosarcoma.
肋骨软骨肉瘤是一种罕见疾病。尽管手术是唯一的治愈性治疗选择,但进行具有足够切缘的肋骨切除术具有挑战性,且局部复发是常见问题。本研究报告了原发性和复发性肋骨软骨肉瘤的预后情况。
对1984年至2014年期间在荷兰三个主要三级转诊中心接受肋骨软骨肉瘤治疗的患者进行回顾性分析。使用Kaplan-Meier法和Cox比例风险分析法分析临床和组织病理学特征的预后价值。终点设定为局部复发性疾病、转移率或死亡。
总体而言,76例患者接受了原发性软骨肉瘤切除术,26例患者接受了复发性软骨肉瘤切除术。原发性组的5年总生存率为90%,局部复发率为17%,转移率为12%。复发性软骨肉瘤后的5年结局较差,总生存率为65%,局部复发率为27%,转移率为27%。对于原发性软骨肉瘤,肿瘤大小>5 cm和切缘阳性与较差的总生存率相关[风险比(HR)3.28,95%置信区间(CI)1.03 - 10.44;HR 2.92,95% CI 1.03 - 8.25]。较高的组织学分级与较高的局部复发和转移率相关(HR 5.92,95% CI 1.11 - 31.65;HR 6.96,95% CI 1.15 - 42.60)。
手术切除原发性和复发性肋骨软骨肉瘤是一种有效的治疗策略。对于肿瘤大小>5 cm、切缘阳性的肿瘤和3级软骨肉瘤,手术后的肿瘤学结局较差